Lung cancer in patients under age 40

Skarin, Arthur T.; Herbst, Roy S.; Leong, Traci; Bailey, Allison; Sugarbaker, David J.

doi:10.1016/s0169-5002(00)00233-6

Cited by 66 publications

(64 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[12][13][14][15][16][17][18][19][20][21][22] In our study, the percentage of adenocarcinoma in the young male subgroup was significantly higher than that of the whole group. Although this analysis lacks a detailed smoking history, we think smoking is a major factor for this phenomenon.…”

Section: Discussionmentioning

confidence: 80%

“…[12][13][14] However, previous studies have provided scant and discordant data about the clinical characteristics and prognoses of young patients with lung cancer. [12][13][14][15][16][17] We found several interesting characteristics of young patients with lung cancer in the current study. The percentage of adenocarcinoma in the young male subgroup was significantly higher than that in the group of all men with lung cancer.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

Zhang

Chen

Zhen

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:The treatment, prognosis, and outcomes of young lung cancer patients have not been fully explored. In addition, there is a pressing need to characterize this subgroup of patients, because there is a trend of increasing incidence in younger patients from Europe and Japan. METHODS: Consecutive, nonselected young patients (<45 years old) with pathologically diagnosed lung cancer treated at 175 qualified hospitals in the greater Shanghai area were included in this analysis. Incidence, prognostic factors, and treatment outcome of lung cancer patients from 2002 to 2006 were documented. A comparison with lung cancer patients of any age was also made. RESULTS: A total of 12,380 patients with nonsmall cell lung cancer were registered. Among them, 652 patients were between 15 and 45 years old. One-year, 3-year, and 5-year survival rates of lung cancer patients younger than 45 years were 49.87%, 26.68%, and 23.12%, respectively. TNM stage, treatment hospital (tertiary vs community hospital), sex, and cancer histology were confirmed as independent prognostic factors. Compared with lung cancer patients of any age in Shanghai, the percentage of adenocarcinoma in the young male subgroup was significantly higher (63.77% vs 43.19%, P < .001). Interestingly, median survival time of young lung cancer patients was similar with that of lung cancer patients of any age, but was significantly shorter than the median survival of middle-aged patients (45-60 years old). CONCLUSIONS: Median survival of the middle-aged group (45-60 years) was significantly longer than the young group (<45 years) and the old group (>60 years). Therefore, aggressive treatment modalities should be strongly considered for young lung cancer patients. Cancer 2010;116;3656-62.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 93%

Multicenter analysis of lung cancer patients younger than 45 years in Shanghai

Zhang

Chen

Zhen

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…There have been numerous papers focused on young NSCLC patients, each with varying definitions of "young" [5][6][7][8]. Some of these studies attempted to compare outcomes between younger and older NSCLC patients.…”

Section: Introductionmentioning

confidence: 99%

Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis

Lara¹,

Brunson

Wun

et al. 2014

Lung Cancer

View full text Add to dashboard Cite

“…Before the introduction of highly active antiretroviral therapy (HAART), patients with HIV-related NSCLC had a worse outcome compared to age-matched HIV-negative controls (Sridhar et al, 1992;Vyzula and Remick, 1996;Tirelli et al, 2000). It has been suggested that this increased mortality was because the patients were younger, and had both more advanced and more aggressive disease compared to HIV-negative patients (Sridhar et al, 1992;Vyzula and Remick, 1996;Whooley et al, 1999;Skarin et al, 2001). Others have speculated that individuals with HIV-related lung cancer were offered suboptimal treatment due to concerns surrounding HIV-related comorbidity (Tirelli et al, 2000).…”

mentioning

confidence: 99%